Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Testing effectiveness (Phase 2)Study completedNCT02694822
What this trial is testing

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Who this might be right for
Advanced Solid CancersAdvanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies
Agenus Inc. 89
Testing effectiveness (Phase 2)Active Not RecruitingNCT05605496
What this trial is testing

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies

Who this might be right for
Advanced Solid TumorsMetastatic Solid Tumors
Centre Leon Berard 57
Testing effectiveness (Phase 2)Active Not RecruitingNCT03607890
What this trial is testing

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Who this might be right for
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 TherapyMSI-H Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 38
Testing effectiveness (Phase 2)Study completedNCT04819373
What this trial is testing

BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors

Who this might be right for
Tumor, Solid
Eikon Therapeutics 1
Early research (Phase 1)Looking for participantsNCT05410717
What this trial is testing

CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
Stage IV Ovarian CancerTestis Cancer, RefractoryEndometrial Cancer Recurrent+1 more
Second Affiliated Hospital of Guangzhou Medical University 200
Early research (Phase 1)Ended earlyNCT04795713
What this trial is testing

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Who this might be right for
Advanced Solid TumorNon-small Cell Lung CancerSquamous Cell Carcinoma of Head and Neck
Molecular Templates, Inc. 64